Structure based lead optimization approach in discovery of selective DPP4 inhibitors

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 6, 2013, Pages 888-914

  Ghate, Manjunath ^a   Jain, Shailesh V ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4; Lead optimization

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LEAD; LINAGLIPTIN; MELOGLIPTIN; METFORMIN; PIOGLITAZONE; PSN 9301; SAXAGLIPTIN; SEPRASE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; WARFARIN;

BACKACHE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BINDING SITE; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN SECONDARY STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REACTION OPTIMIZATION; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SORE THROAT; STOMACH PAIN; SWEATING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR;

EID: 84876741806     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313060010     Document Type: Review

References (175)

1. Jeff Unger, M.D., Current Strategies for Evaluating, Monitoring, and Treating Type 2 Diabetes Mellitus, The American Journal of Medicine, 2008, 121(6A).
2. World Health Organization at World Health Organization at http://www.who.int/diabetes/facts/world_figures/en/.
3. Bloomgarden, Z. T. Approaches to Treatment of Type 2 Diabetes, Diabetes Care, 2008, 31(8), 1697-1703.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 977-986.
5. Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus, Geneva, pp. 59, WHO/NCD/NCS/99.2.
6. th Ed., BMJ Publishing Group Ltd, BMA House, Tavistock Square, London, 2003, 2-14.
7. Morral, N. Novel targets and therapeutic strategies for type 2 diabetes, Trends in Endo. Meta., 2003, 14(4), 169-175.
8. Nathan, D. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002, 347, 1342-1349.
9. Krentz, A.J.; Baily, C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
10. Rosenstock, J.; Sugimoto, D.; Strange, P. Triple therapy in type 2 diabetes: insulin glargine or rosaglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care, 2006, 29, 54-559.
11. Tahrani, A. A.; Piya M. K.; Kennedy A.; Barnett A. H., Glycaemic control in type 2 diabetes: Targets and new therapies, Pharmaco. & Thera., 2010, 125, 328-361.
12. Geelhoed-Duijvestijn P.H. Incretins: a new treatment option for type 2 diabetes? Neth J Med. 2007, 65, 60-64.
13. Drucker, D. J. Enhancing Incretin Action for the Treatment of Type 2 Diabetes, Diabetes Care, 2003, 26(10), 2929-40.
14. Barnett, A. H., New treatments in type 2 diabetes a focus on the incretin-based therapies. Clin Endocrinol (Oxf). 2009, 70(3), 343-53.
15. Holst, J. J.; Deacon C. F. Glucagon-like peptide peptide-1 mediates the therapeutic actions of DPP-IV inhibitors, Diabetologia, 2005, 48, 612-615.
16. Verspohl, E.J. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics, Pharmaco. & Thera., 2009, 124, 113-138.
17. Davidson, M. B.; Bate, G.; Kirkpatrick, P. Exenatide, Nat. Rev. Drug Disc. 2005, 4, 713.
18. Wua, J.; Chenb, Y.; Shia, X.; Gua, W. Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes, J. Nanjing Medical Uni. 2009, 23(4), 228-235.
19. McIntosh, C.H.S.; Demuthb, H.U.; Kim, S.J.; Pospisilik J. A.; Pederson R. A. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus, Int. J. Biochem. & Cell Bio. 2006, 38, 860-872.
20. Drucker, D. J.; Sherman, S. I.; Gorelick, F. S.; Bergenstal, R. M.; Sherwin, R. S.; Buse, J. B. Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits, Diabetes care, 2010, 33(2), 453-455.
21. Morral, N. Novel targets and therapeutic strategies for type 2 diabetes, Trends in Endo. Meta. 2003, 14(4), 169-75.
22. Gaba M.; Singh S.; Gaba P., dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment. Int. J. drug Dev & Res., 2009, 1(1), 146-156.
23. Mistry, G. C., Bergman, A. J., Zheng, W., Hreniuk, D., Zinny, M. A., Gottesdiener, K. M., Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol, 2008, 66, 36-42.
24. Mohan, V., Yang, W., Son, H. Y., Xu, L., Noble, L., Langdon, R. B., Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract, 2009, 83, 106-116.
25. Heise, T.; Graefe-Mody, E.U.; Huttner, S.; Ring, A.; Trommeshauser, D.; Dugi, K.A. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009, 11(8), 786-94.
26. Chyan, Y.; Chuang, L. Dipeptidyl Peptidase-IV Inhibitors: An Evolving Treatment for Type 2 Diabetes from the Incretin Concept, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 15-24.
27. Lambeir, A. M.; Scharpe, S.; Meester, I. D. DPP4 inhibitors for diabetes-What next? Bio chemical pharmaco, 2008, 76, 1637-1643.
28. Baxter, A. D.; Lockey P. M., 'Hit' to 'lead' and 'lead' to 'candidate' optimization using multi-parametric principles, Drug Dis. World Winter 2001, 2, 9-15.
29. Lu, I.L.; Tsai, K. C.; Chiang, Y.K.; Jiaang, W. T.; Wu, S. H.; Mahindroo, N.; Chien, C.H.; Lee, S.J.; Chen, X.; Chao, Y.S.; Wu, S. Y. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors, Euro. J. Med. Chem., 2008, 43, 1603-1611.
30. Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I. Hit and Laed generation: Beyond high-throughput screening, Nature Review, Drug Disc., 2003, 2, 369-378.
31. Keseru, G. M.; Makara, G. M. Hit discovery and hit-to-lead approaches, Drug Discovery Today 2006, 11(15/16).
32. Rao, V. S.; Srinivas, K. Modern drug discovery process: An in silico approach, J. Bioinform. Sequence Ana. 2011, 2(5), 89-94.
33. Síedo, A.; Radek, M., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?, Biochimica et Biophysica Acta, 2001, 1550, 107-116.
34. Hopsu-Havu, V.K.; Glenner, G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie, 1966, 7, 197-201.
35. Deacon, C. F.; Holst, J. J. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem. Biophysical Research Comm., 2002, 294, 1-4.
36. Weber, A. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem., 2004, 47, 4135-41.
37. Chien, C. H., Huang, L. H., Chou, C.Y., Chen, Y. S., Han, Y. S., Chang, G. G., One site mutation disrupts dimer formation in human DPP-IV proteins. J. Bio. Chem., 2004, 279(50), 52338-52345.
38. P̈uschel, G., Mentlein, R., & Heymann, E. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Euro. J. Biochem., 1982, 126(2), 359-365.
39. Thoma, R., Loffler, B., Stihle, M., Huber, W., Ruf, A., & Hennig, M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure, 2003, 11(8), 947-959.
40. Hinke, S. A., Pospisilik, J. A., Demuth, H. U., Mannhart, S., K̈uhn-Wache, K., Hoffmann, T., Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon, Characterization of glucagon degradation products and DPIV-resistant analogs, J. Bio. Chem., 2000, 275(6), 3827-3834.
41. Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X. M., Bollaert, W., The unique properties of dipeptidylpeptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors, Current Med. Chem., 1999, 6(4), 311-327.
42. Ambeir, A. M., Durinx, C., Scharpe, S., & De Meester, I. Dipeptidylpeptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews Clinical Lab. Sciences, 2003, 40(3), 209-294.
43. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulatory Peptides, 1999, 85(1), 9-24.
44. Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagonlike peptide- 1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Euro. J. Biochem., 1993, 214(3), 829-835.
45. Rettig, W.J.; Su, S.L.; Fortunato, S.R.; Scanlan, M.J.; Mohan Raj B.K.; Garin-Chesa, P.; Healey, J.H.; Old, L.J., Fibroblast activation protein: Purification, epitope mapping and induction by growth factors. Int. J. Cancer, 1994, 58, 385-392.
46. Park, J.E.; Lenter, M.C.; Zimmermann, R.N.; Garin-Chesa, P.; Old, L.J.; Rettig, W.J. Fibroblast activation protein, a dual specificity serine protease expressed in relative human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274, 36505-36512.
47. Rettig, W.J.; Garin-Chesa, P.; Healey, J.H.; Su, S.L.; Ozer, H.L.; Schwab, M.; Albino, A.P.; Old, L.J., Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin, Cancer Res., 1993, 53, 3327-3335.
48. McDonald, J.K.; Ellis, S.; Reilly, T.J. Properties of dipeptidyl arylamidase I of the pituitary. Chloride and sulfhydryl activation of seryltyrosyl-β-naphthylamide hydrolysis. J. Biol. Chem. 1966, 241(7), 1494-501.
49. McDonald, J.K., Reilly, T.J., Zeitman, B.B., Ellis, S. Dipeptidyl arylamidase II of the pituitary. Properties of lysylalanyl-β- naphthylamide hydrolysis: inhibition by cations, distribution in tissues, and subcellular localization. J. Biol. Chem. 1968, 243(8), 2028-37.
50. McDonald, J.K.; Leibach, F.H.; Grindeland, R.E.; Ellis, S. Purification of dipeptidyl aminopeptidase II (dipeptidyl arylamidase II) of the anterior pituitary gland. Peptidase and dipeptide esterase activities. J. Biol. Chem., 1968, 243(15), 4143-50.
51. Eisenhauer, D.A.; McDonald, J.K. A novel dipeptidyl peptidase II from the porcine ovary. Purification and characterization of a lysosomal serine protease showing enhanced specificity for prolyl bonds. J. Biol. Chem., 1986, 261(19), 8859-65.
52. Kato, T.; Hama, T.; Nagatsu, T. Separation of two dipeptidyl aminopeptidases in the human brain. J. Neurochem. 1980, 34(3), 602-8.
53. Hopsu-Havu, V.K.; Jansen, C.T., Jarvinen, M. Partial purification and characterization of an acid dipeptide naphthylamidase (carboxytripeptidase) of the rat skin. Arch Klin Exp Dermatol, 1970, 236(3), 282-96.
54. Chiravuri, M; Schmitz, T; Yardley, K; Underwood, R.; Dayal, Y.; Huber, B.T. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol, 1999, 163(6), 3092-9.
55. Maes, M.B.; Lambeir, A.M.; Gilany, K. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J., 2005, 386, 315-24.
56. Yaron, A.; Naider, F. Proline-dependent structural and biological properties of peptides and proteins, Crit. Rev. Biochem. Mol. Biol. 1993, 28, 31-81.
57. Abbott, C.A.; Yu, D.M.; Woollatt, E.; Sutherland, G.R.; McCaughan, G.W.; Gorrell, M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8, Eur. J. Biochem. 2000, 267, 6140-6150.
58. Tang, W.; Gunn, T.M.; McLaughlin, D.F.; Barsh, G.S.; Schlossman, S.F.; Duke-Cohan, J.S.,Secreted and membrane attractin result from alternative splicing of the human ATRN gene, Proc. Natl. Acad. Sci. USA, 2000, 97, 6025-6030.
59. Malik, R.; Mares V.; Kleibl, Z.; Pohlreich, P.; Vlas-icova, K.; Síedo, A. Expression of attractin and its differential enzyme activity in glioma cells, Biochem. Biophys. Res. Commun. 2001, 284, 289-294.
60. Wrenger, S.; Faust, J.; Mrestani-Klaus, C.; Fengler, A.; Stockel-Maschek, A.; Lorey, S.; Kahne, T.; Brandt, W.; Neubert, K.; Ansorge, S.; Reinhold, D. Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the Nterminal part of the thromboxane A2 receptor, J. Biol. Chem. 2000, 275, 22180-22186.
61. Lankas, G. R. et al., Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes, Diabetes, 2005, 54, 2988-94.
62. Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U., Trappe, J.; Juedes, M.; Foley, J. E., Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited, 2008, 10(11), 1057-1061.
63. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, PNAS, 2003, 100(9), 5063-5068.
64. Medrano, F. J., Alonso, J., Garcia, J. L., Romero, A., Bode, W. & Gomis-R̈uth, F. X. Structure of proline iminopeptidase from Xanthomonas campestris pv. citri: a prototype for the prolyl oligopeptidase family, EMBO J., 1998, 17, 1-9.
65. Ito, K., Inoue, T., Kabashima, T., Kanada, N., Huang, H.-S., Ma, X., Azmi, N., Azab, E. & Yoshimoto, T. Substrate recognition mechanism of prolyl aminopeptidase from Serratia marcescens, J. Biochem. 2000, 128, 673-678.
66. Goettig, P., Groll, M., Kim, J.-S., Huber, R. & Brandstetter, H. Structures of the tricorn-interacting aminopeptidase F1 with different ligands explain its catalytic mechanism, EMBO J., 2002, 21, 5343-5352.
67. Kang, N. S.; Ahn, J. H.; Kim, S. S.; Chae C. H.; Yoo, S.E. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors, Bioorg. Med. Chem. Lett., 2007, 17, 3716-3721.
68. Janardhan, S.; Padmanabha Reddy, Y. Homology modeling and molecular docking studies of human dpp-8 and dpp-9, IJPRD, 2011, 2(12), 131-146.
69. Havale, S. H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes, Bioorg. Med. Chem. 2009, 17, 1783-1802.
70. Simpkins, L.; Bolton, S.; Pi, Z.; Scutton, J.; Kwon, C.; Magnin, D.; Augeri, D.; Gungor, T. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6476-6480.
71. Veken, P. V.; Haemers, A.; Augustyns, K. Prolyl peptidase related to dipeptidyl peptidase IV: Potential of specific inhibitors in drug discovery. Current Topics in Med. Chem. 2007, 7, 621-635.
72. Dpp-4 inhibitors- A global strategic business report http://www.strategyr.com/DPP_IV_Inhibitors_Market_Report.asp
73. Santosh K.S.; Narendra M.; Pal M. Synthesis of (S)-1-(2- chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors, Beilstein Journal of Organic Chemistry, 2008, 4(20), doi:10.3762/bjoc.4.20.
74. Peters, J.U. 11 years of Cyanopyrrolidines as DPP-IV Inhibitors. Current topics in Medicinal Chemistry, 2007, 7, 579-595.
75. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D. 4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, Bioorg. Med. Chem. Lett. 1996, 6, 2745-2748.
76. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Hughes, T. E. 1-[2-[(5-Cyanopyridin-2- yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties J. Med. Chem. 2002, 45, 2362.
77. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano- (S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties J. Med. Chem. 2003, 46, 2774.
78. Royalty, S. M.; Burns, J. F.; Scicinski, J. J.; Jagdmann, G. E., Jr.; Foglesong, R. J.; Griffin, K. R.; Dyakonov, T.; Middlemiss, D. World Patent Application no. WO2006/012395, February 2, 2006.
79. Tsu, H.; Chen, X.; Chen, C. T.; Lee, S.-J.; Chang, C.-N.; Kao, K.-H.; Coumar, M. S.; Yeh, Y.-T.; Chien, C.-H.; Wang, H.-S.; Lin, K.-T.; Chang, Y.-Y.; Wu, S.-H.; Chen, Y. S.; Lu, I.-L.; Wu, S.-Y.; Tsai, T.-Y.; Chen, W.-C.; Hsieh, H.-P.; Chao, Y.-S.; Jiaang, W. T.,2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2006, 49, 373-80
80. Damon, R., Tetrahydroisoquinoline 3-carboxamide derivatives U.S. 6,172,081, 2001.
81. Lu, I.-L.; Lee, S.-J.; Tsu, H.; Wu, S.-Y.; Kao, K.-H.; Chien, C.-H.; Chang, Y.-Y.; Chen, Y.-S.; Cheng, J.-H.; Chang, C.-N.; Chen, T.-W.; Chang, S.-P.; Chen, X.; Jiaang, W.-T. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors, Bioorg. Med. Chem. Lett. 2005, 15, 3271.
82. Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G., Discovery and preclinical profile of Saxagliptin (BMS- 477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 2005, 48(15), 5025-37.
83. Zhao, G.; Taunk, P. C.; Magnin, D. R.; Simpkins, L. M.; Robl, J. A.; Wang, A.; Robertson, J. G.; Marcinkeviciene, J.; Sitkoff, D. F.; Parker, R. A.; Kirby, M. S.; Hamann, L. G., Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2005, 15(18), 3992-95.
84. Haffner, C. D.; McDougald, D. L.; Reister, S. M.; Thompson, B. D.; Conlee, C.; Fang, J.; Bass, J.; Lenhard, J. M.; Croom, D.; Secosky-Chang, M. B.; Tomaszek, T.; McConn, D.; Wells-Knechtd, K.; Johnson, P. R., 2-Cyano-4-fluoro-1- thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV, Bioorg. Med. Chem. Lett. 2005, 15(23), 5257-61.
85. Fukushima, H.; Hiratate, A.; Takahashi, M.; Saito, M.; Munetomo, E.; Kitano, K.; Saito, H.; Takaoka, Y.; Yamamoto, K., Synthesis and structure-activity relationships of potent 3- or 4-substituted-2- cyanopyrrolidine dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem., 2004, 12(23), 6053-61.
86. Fukushima, H.; Hiratate, A.; Takahashi, M.; Mikami, A.; Saito-Hori, M.; Munetomo, E.; Kitano, K.; Chonan, S.; Saito, H.; Suzuki. Takaoka, Y.; Yamamoto, K., Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. 2008, 16(7), 4093-106.
87. Gopalan, B.; Joshi, H. V.; Shah, D. M.; Ghorpade, S. R. PCT Int. Appl. WO 2005/033099, April 14, 2005.
88. Aranyl, P.; Bata, I.; Batori, S.; Boronkay, E.; Bovy, P.; Kapui, Z.; Susan, E.; Szabo, T.; Urban-Szabo, K.; Varga, M. World Patent Application no. WO 2005/021536, March 10, 2005.
89. Sattigeri, J. A.; Andappan, M. M. S.; Kishore, K.; Thangathirupathy, S.; Sundaram, S.; Singh, S.; Sharma, S.; Davis, J. A.; Chugh, A.; Bansal, V. S., Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(14), 4087-91.
90. Sakashita, H.; Kitajima, H.; Nakamura, M.; Akahoshi, F.; Hayashi, Y., 1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitor, Bioorg. Med. Chem. Lett. 2005, 15(10), 2441-5.
91. Kondo, T.; Sugimoto, I.; Nekado, T.; Ochi, K.; Ohtani, T.; Tajima, Y.; Yamamoto, S.; Kawabata, K.; Nakai, H.; Toda, M., Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV, Bioorg. Med. Chem. 2007, 15(7), 2715-35.
92. Tsai, T.Y.; Coumar, M. S.; Hsu, T.; Hsieh, H.P.; Chien, C.H.; Chen, C.T.; Chang, C.N.; Lo, Y.K.; Wu, S.H.; Huang, C.Y.; Huang, Y.W.; Wang, M.H.; Wu, H.Y.; Lee, H.J.; Chen, X.; Chao, Y.S.; Jiaang, W.T., Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(12), 3268-72.
93. Pei, Z.; Li, X.; Longenecker, K.; von Geldern, T. W.; Wiedeman, P. E.; Lubben, T. H.; Zinker, B. A.; Stewart, K.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W. A.; Long, M.; Wells, H.; Kempf-Grote, A. J.; Madar, D. J.; McDermott, T. S.; Bhagavatula, L.; Fickes, M. G.; Pireh, D.; Solomon, L. R.; Lake, M. R.; Edalji, R.; Fry, E. H.; Sham, H. L.; Trevillyan, J. M., Discovery, structure-activity relationship, and pharmacological evaluation of (5-substitutedpyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors, J. Med. Chem. 2006, 49(12), 3520-35.
94. Corbett, J. W.; Dirico, K.; Song, W.; Boscoe, B. P.; Doran, S. D.; Boyer, D.; Qiu, X.; Ammirati, M.; VanVolkenburg, M. A.; McPherson, R. K.; Parker, J. C.; Cox, E. D., Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2- cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors, Bioorg. Med. Chem. Lett. 2007, 17(24), 6707-13.
95. Wright, S. W.; Ammirati, M. J.; Andrews, K. M.; Brodeur, A. M.; Danley, D. E.; Doran, S. D.; Lillquist, J. S.; McClure, L. D.; McPherson, R. K.; Orena, S. J.; Parker, J. C.; Polivkova, J.; Qiu, X.; Soeller, W. C.; Soglia, C. B.; Treadway, J. L.; VanVolkenburg, M. A.; Wang, H.; Wilder, D. C.; Olson, T. V., cis-2,5- dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and X-ray crystallographic characterization, J. Med. Chem. 2006, 49(11), 3068-76.
96. Madar, D. J.; Kopecka, H.; Pireh, D.; Yong, H.; Pei, Z.; Li, X.; Wiedeman, P.; Djuric, S. W.; von Geldern, T. W.; Fickes, M.; Bhagavatula, L.; McDermott, T.; Wittenberger, S.; Longenecker, K.; Stewart, K.; Lubben, T. H.; Ballaron, S. J.; Stashko, M. A.; Long, M.; Wells, H.; Zinker, B. A.; Mika, A. K.; Beno, D. W. A.; Kempf-Grote, A. J.; Polakowski, J.; Segreti, J.; Reinhart, G. A.; Fryer, R.; Sham, H. L.; Trevilliyan, J. M., Discovery, structureactivity relationship, and pharmacological evaluation of (5- substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors, J. Med. Chem. 2006, 49(12), 3520-35.
97. Edmondson, S. D.; Mastracchio, A.; Duffy, J. L.; Eiermann, G. J.; He, H.; Ita, I.; Leiting, B.; Leone, J. F.; Lyons, K. A.; Makarewicz, A. M.; Patel, R. A.; Petrov, A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E., Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2005, 15(12), 3048-52.
98. Edmondson, S. D.; Mastracchio, A.; Mathvink, R. J.; He, J.; Harper, B.; Park, Y.-J.; Beconi, M.; Di Salvo, J.; Eiermann, G. J.; He, H.; Leiting, B.; Leone, J. F.; Levorse, D. A.; Lyons, K.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Shang, J.; Sinha Roy, R.; Smith, A.; Wu, J. K.; Xu, S.; Zhu, B.; Thornberry, N. A.; Weber, A. E., (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N- dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6- ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 2006, 49(12), 3614-27.
99. Duffy, J. L.; Kirk, B. A.; Wang, L.; Eiermann, G. J.; He, H.; Leiting, B.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Weber, A. E., 4- aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV, Bioorg. Med. Chem. Lett. 2007, 17(10), 2879-85.
100. Kaelin, D. E.; Smenton, A. L.; Eiermann, G. J.; He, H.; Leiting, B.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Webera, A. E.; Duffy, J. L., 4- arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV, Bioorg. Med. Chem. Lett. 2007, 17(21), 5806-11.
101. Caldwell, C. G.; Chen, P.; He, J.; Parmee, E. R.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Eiermann, G. J.; Petrov, A.; He, H.; Lyons, K.; Thornberry, N. A.; Weber, A. E., Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2004, 14, 1265-8.
102. Ashton, W. T.; Dong, H.; Sisco, R. M.; Doss, G. A.; Leiting, B.; Patel, R. A.; Wu, J. K.; Marsilio, F.; Thornberry, N. A.; Weber, A. E., Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2004, 14(4), 859-63.
103. Xu, J.; Wei, L.; Mathvink, R.; Edmondson, S. D.; Mastracchio, A.; Eiermann, G. J.; He, H.; Leone, J. F.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E., Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors, Bioorg. Med. Chem. Lett. 2006, 16(5), 1346-9.
104. Xu, J.; Wei, L.; Mathvink, R. J.; Edmondson, S. D.; Eiermann, G. J.; He, H.; Leone, J. F.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Weber, A. E., Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2006, 16(20), 5373-77.
105. Hulin, B.; Cabral, S.; Lopaze, M. G.; Van Volkenburg, M. A.; Andrews, K. M.; Parker, J. C., New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2005, 15(21), 4770-73.
106. Snow, R. J.; Bachovchin, W. W., Boronic acid inhibitors of dipeptidyl peptidase IV: A new class of immunosuppressive agents, Adv. Med. Chem. 1995, 3, 149-177.
107. Hu, Y.; Ma, L.; Wu, M.; Wong, M. S.; Li, B.; Corral, S.; Yu, Z.; Nomanbhoy, T.; Alemayehu, S.; Fuller, S. R.; Rosenblum, J. S.; Rozenkrants, N.; Minimo, L. C.; Ripka, W. C.; Szardenings, A. K.; Kozarich, J. W.; Shreder, K. R., Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7, Bioorg. Med. Chem. Lett. 2005, 15(19), 4239-42.
108. Tran, T.; Quan, C.; Edosada, C. Y.; Mayeda, M.; Wiesmann, C.; Sutherlin, D.; Wolf, B. B., Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP, Bioorg. Med. Chem. Lett. 2007, 17(5), 1438-42.
109. Sorbera, L. A.; Revel, L.; Castaner, J. P32/98, Drugs Future 2001, 26, 859.
110. Sakashita, H.; Akahoshi, F.; Kitajima, H.; Tsutsumiuchi, R.; Hayashi, Y., [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. Bioorg. Med. Chem. 2006, 14(11), 3662-71.
111. Kondo, T.; Nekado, T.; Sugimoto, I.; Ochi, K.; Takai, S.; Kinoshita, A.; Hatayama, A.; Yamamoto, S.; Kishikawa, K.; Nakai, H.; Toda, M., Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg. Med. Chem. 2008, 16(4), 1613-31.
112. Xu, J.; Ok, H. O.; Gonzalez, E. J.; Colwell, L. F., Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyona, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Discovery of potent and selective -homophenylalanine based dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2004, 14(18), 4759-62.
113. Brockunier, L.; He, J.; Colwell, L. F., Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R.; Teffera, Y.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R., Substituted piperazines as novel dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2004, 14(18), 4763-66.
114. Kim, D.; Kowalchick, J. E.; Edmondson, S. D.; Mastracchio, A.; Xu, J. M.; Eiermann, G. J.; Leiting, B.; Wu, J. K.; Pryor, K.; Patel, R. A.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E., Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate), Bioorg. Med. Chem. Lett. 2007, 17(12), 3373-77.
115. Kim, D.; Kowalchick, J. E.; Brockunier, L. L.; Parmee, E. R.; Eiermann, G. J.; Fisher, M. H.; He, H.; Leiting, B.; Lyons, K.; Scapin, G.; Patel, S. B.; Petrov, A.; Pryor, K.D.; Roy, R. S.; Wu, J. K.; Zhang, X.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E., Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from -aminoamides bearing subsituted triazolopiperazines, J. Med. Chem. 2008, 51(3), 589-602.
116. Kowalchick, J. E.; Leiting, B.; Pryor, K. D.; Marsilio, F.; Wu, J. K.; He, H.; Lyons, K. A.; Eiermann, G. J.; Petrov, A.; Scapin, G.; Patel, R. A.; Thornberry, N. A.; Weber, A. E.; Kim, D. Bioorg. Med. Chem. Lett. 2007, 17, 5934.
117. Chen, P.; Caldwell, C. G.; Mathvink, R. J.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E., Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors, Bioorg. Med. Chem. Lett. 2007, 17(21), 585-89.
118. Chen, P.; Caldwell, C. G.; Mathvink, R. J.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E., Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes, Bioorg. Med. Chem. Lett. 2007, 17(21), 5853-57.
119. Ahn, J. H.; Kim, J. A.; Kim, H. M.; Kwon, H. M.; Huh, S. -C.; Rhee, S. D.; Kim, K. R.; Yang, S. -D.; Park, S.-D.; Lee, J. M.; Kim, S. S.; Cheon, H. G., Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors, Bioorg. Med. Chem. Lett. 2005, 15(5), 1337-40.
120. Ahn, J. H.; Shin, M. S.; Jun, M. A.; Jung, S. H.; Kang, S. K.; Kim, K. P.; Rhee, S. D.; Kang, N. S.; Kim, S. Y.; Sohn, S.-K.; Kim, S. G.; Jin, M. S.; Lee, J. O.; Cheon, H. G.; Kim, S. S., Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors, Bioorg. Med. Chem. Lett. 2007, 17(9), 2622-28.
121. Jun, M. A.; Park, W. S.; Kang, S. K.; Kim, K. Y.; Kim, K. R.; Rhee, S. D.; Bae, M. A.; Kang, N. S.; Sohn, S.-K.; Kim, S. G.; Lee, J. O.; Lee, D. H.; Cheon, H. G.; Kim, S. S.; Ahn, J. H., Synthesis and biological evaluation of pyrazoline analogues with β-amino acyl group as dipeptidyl peptidase IV inhibitors, Eur. J. Med. Chem. 2008, 43(9), 1889-902.
122. Biftu, T.; Feng, D.; Qian, X.; Liang, G.-B.; Kieczykowski, G.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Scapin, G.; Patel, S.; Gao, Y.-D.; Singh, S.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E., (3R)-4-[(3R)- 3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2- trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, Bioorg. Med. Chem. Lett. 2007, 17(1), 49-52.
123. Liang, G.-B.; Qian, X.; Feng, D.; Biftu, T.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E., Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes, Bioorg. Med. Chem. Lett 2007, 17(7), 1903-07.
124. Hansotia, T.; Baggio, L. L.; Delmeire, D.; Hinke, S. A.; Yamada, Y.; Tsukiyama, K.; Seino, Y.; Holst, J. J.; Schuit, F.; Drucker, D. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors, J. Diabetes 2004, 53(5), 1326-35.
125. Eckhardt, M.; Langkopf, E.; Mark, M.; Tadayyon, M.; Thomas, L.; Nar, H.; Pfrengle, W.; Guth, B.; Lotz, R.; Sieger, P.; Fuchs, H.; Himmelsbach, F., 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6- dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 2007, 50(26), 6450-53.
126. Himmelsbach, F.; Langkopf, E.; Eckhardt, M.; Mark, M.; Maier, R.; Lotz, R.; Tadayyon, M. WO 2004018468, 2004.
127. Eckhardt, M.; Hauel, N.; Himmelsbach, F.; Langkopf, E.; Nar, H.; Mark, M.; Tadayyon, M.; Thomas, L.; Guth, B.; Lotz, R., 3,5- Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors, Bioorg. Med. Chem. Lett. 2008, 18, 3158-62.
128. Wallace, M. B.; Feng, J.; Zhang, Z.; Skene, R. J.; Shi, L.; Caster, C. L.; Kassel, D. B.; Xu, R.; Gwaltney, S. L., II Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2008, 18, 2362-67.
129. Scapin, G.; Singh, S.; Feng, D.; Becker, J.; Doss, G.; Eiermann, G.; He, H.; Lyons, K.; Patel, S.; Petrov, A.; Sinha Roy, R.; Shang, B.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E.; Biftu, T. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin, Bioorg. Med. Chem. Lett. 2007, 17, 3384-87.
130. Cox, J. M.; Harper, B.; Mastracchio, A.; Leiting, B.; Roy, R. S.; Patel, R. A.; Wu, J. K.; Lyons, K. A.; He, H.; Xu, S.; Zhu, B.; Thornberry, N. A.; Webera, A. E.; Edmondsona, S. D., Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. Lett. 2007, 17(16), 4579-83.
131. Biftu, T.; Weber, A. E. U.S/2007/0232676 A1, October 4, 2007.
132. Abe, M.; Abe, F.; Nishimura, C.; Ichimura, E.; Ogasawara, A.; Ichinei, M.; Muraoka, Y.; Saino, T. Sulphostin, a novel inhibitor of dipeptidyl peptidases IV (DPPIV) that stimulates hematopoiesis in mice, J. Antibiot. 2005, 58(2), 111-17.
133. Pei, Z.; Li, X.; von Geldern, T. W.; Madar, D. J.; Longenecker, K.; Yong, H.; Lubben, T. H.; Stewart, K. D.; Zinker, B. A.; Backes, B. J.; Judd, A. S.; Mulhern, M.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W. A.; Reinhart, G. A.; Fryer, R. M.; Preusser, L. C.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, J. M., Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabete,. J. Med. Chem. 2006, 49, 6439-42.
134. Backes, B. J.; Longenecker, K.; Hamilton, G. L.; Stewart, K.; Lai, C.; Kopecka, H.; von Geldern, T. W.; Madar, D. J.; Pei, Z.; Lubben, T. H.; Zinker, B. A.; Tian, Z.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W. A.; Kempf-Grote, A. J.; Black-Schaefer, C.; Sham, H. L.; Trevillyan, J. M. Pyrrolidineconstrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit, Bioorg. Med. Chem. Lett. 2007, 17, 2005-12.
135. Pei, Z.; Li, X.; von Geldern, T. W.; Longenecker, K.; Pireh, D.; Stewart, K. D.; Backes, B. J.; Lai, C.; Lubben, T. H.; Ballaron, S. J.; Beno, D. W. A.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitor, J. M. J. Med. Chem. 2007, 50, 1983-87.
136. Lübbers, T.; Böhringer, M.; Gobbi, L.; Hennig, M.; Hunziker, D.; Kuhn, B.; Löffler, B.; Mattei, P.; Narquizian, R.; Peters, J.-U.; Ruff, Y.; Wessel, H. P.; Wyss, P. 1,3-disubstituted 4- aminopiperidines as useful tools in the optimization of the 2- aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors, Bioorg. Med. Chem. 2007, 17(11), 2966-70.
137. Kanstrup, A. B.; Sams, C. K.; Lundbeck, J. M.; Christiansen, L. B.; Kristiansen, M. World Patent 2003004496, 2003.
138. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L., Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2007, 50(10), 2297-300.
139. Oi, S.; Ikedou, K.; Takeuchi, K.; Ogino, M.; Banno, Y.; Tawada, H.; Yamane, T. WO02/062764, 2002.
140. Schade, J.; Stephan, M.; Schmiedl, A.; Wagner, L.; Niestroj, A. J.; Demuth, H.-U.; Frerker, N.; Klemann, C.; Raber, K. A.; Pabst, R.; von Hörsten, S. J., Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. Histochem. Cytochem. 2008, 56(2), 147-155.
141. Rosemblum, J. S.; Minimo, L. C.; Liu, Y.; Wu, J.; Kozarich, J. W. National meeting of the American Diabetes Association, 2007. Diabetes, 2007, 56, A138.
142. Dubois, V.; Lambeir, A. M.; Van der Veken, P.; Augustyns, K.; Creemers, J.; Chen, X.; Scharpé, S.; De Meester, I. Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. Front. Biosci. 2008, 13, 3558-3565.
143. Van der Veken, P.; Soroka, A.; Brandt, I.; Chen, Y. S.; Maes, M. B.; Lambeir, A. M.; Chen, X.; Haemers, A.; Scharpé, S.; Augustyns, K.; De Meester, Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. I. J. Med. Chem. 2007, 50, 5568-70.
144. Veken, P.V.D.; Meester, I.D.; Dubois, V.; Soroka A.; Goethem, S. V.; Maes, M-B.; Brandt, I., Lambeir, A-M.; Chen, X.; Haemers, A.; Scharpé, S.; Augustyns, K. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads. Bioorg. Med. Chem. Lett. 2008, 18, 4154-4158.
145. Goethem S. V.; Veken, P. V. D; Dubois, V.; Soroka A.; Goethem, S. V.; Maes, M-B.; Brandt, I., Lambeir, A-M.; Chen, X.; Haemers, A.; Scharpé, S.; Augustyns, K. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: Isoindoline containing inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4159-4162.
146. Chiravuri, M.; Schmitz, T.; Yardley, K.; Underwood, R.; Dayal, Y.; Huber, B. T. J., A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. Immunol. 1999, 163(6), 3092-9.
147. Underwood, R.; Chiravuri, M.; Lee, H.; Schmitz, T.; Kabcenell, A. K.; Yardley, K.; Huber, B. T. Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J. Biol. Chem. 1999, 274(8), 34053-8.
148. Li, J.; Wilk, E.; Wilk, S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch. Biochem. Biophys. 1995, 323(1), 148-154.
149. Augustyns, K.; Bal, G.; Thonus, G.; Belyaev, A.; Zhang, X. M.; Bollaert, W.; Lambeir, A. M.; Durinx, C.; Goossens, F.; Haemers, The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. A. Curr. Med. Chem. 1999, 6, 311-27.
150. Schö N. E.; Born, I.; Demuth, H. U.; Faust, J.; Neubert, K.; Steinmetzer, T.; Barth, A.; Ansorge, S. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe-Seyler, 1991, 372(5), 305-11.
151. Stöckel-Maschek, A.; Mrestani-Klaus, C.; Stiebitz, B.; Demuth, H.-U.; Neubert, K., Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim. Biophys. Acta, 2000, 1479, 15-31.
152. Senten, K.; Veken, P. V. D.; Bal, G.; Meester, I.D.; Lambeir, A.-M.; Scharpe, S.; Bauvois, B, Haemersa, A.; Augustynsa, K. Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, Bioorg. Med. Chem. Lett. 2002, 12, 2825-2828.
153. Aertgeerts, K.; Levin, I.; Shi, L.; Snell, G.P.; Jennings, A.; Prasad, G.S.; Zhang, Y.; Kraus, M.L.; Salakian, S.; Sridhar, V.; Wijnands, R.; Tennant, M.G., Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J. BioI. Chern., 2005, 280(20), 19441-4.
154. Garin-Chesa P.; Old, L.J.; Rettig, W.J., Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U. S. A., 1990, 87, 7235-9.
155. Cheng, J. D.; Dunbrack, R. L.; Valianou, M.; Rogatko, A; Alpaugh, R. K.; Weine, L. M., Promotion of Tumor Growth by Murine Fibroblast Activation Protein, a Serine Protease, in an Animal Model. Cancer Res., 2002, 62, 4767-72.
156. Adams, S.; Miller, G.T.; Jesson, M.I.; Watanabe, T.; Jones, B.; Wallner, B. P., PT- 100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism. Cancer Res., 2004, 64, 5471-80.
157. Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.A.; Sandqvist, M.; Bavenholm, P., Efendic, S.; Eriksson, J.W. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 2002, 25, 869-875.
158. Ahren, B.; Landin-Olsson, M.; Jansson, P.A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 2078-2084.
159. Ahrén, B.; Foley, J. E.; Bos, E., Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes, Obes Metab, 2011, 13(3), 193-203
160. Schweizer A, Dejager S., Foley J. E, Couturier, A.; Ligueros-Saylan, M.; Kothny, W. Assessing the cardio-cerebrovascular safety of vildagliptin: metaanalysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, Obes Metab, 2010, 12(6), 485-494.
161. Ligueros-Saylan, M; Foley, J. E.; Schweizer, A.; Couturier, A.; Kothny, W, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes, Obesity and Metabolism, 2010, 12(6), 495-509.
162. He, Y.L.; Sadler, B.M.; Sabo, R.; Balez, S.; Wang, Y.; Campestrini, J.; Laurent, A.; Ligueros-Saylan, M. and Howard, D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin. Pharmacokinet., 2007, 46, 787-802.
163. Todd, J.F. and Bloom, S.R. Incretins and other peptides in the treatment of diabetes. Diabet. Med., 2007, 24, 223-32.
164. Xu, L.; Man, C.D.; Charbonnel, B.; Meninger, G.; Davies, M.J.; Williams, H.D.; Cobelli, C. and Stein, P.P. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach Diabetes Obes. Metab., 2008, 10, 1212-1220.
165. Scott, R.; Wu, M.; Sanchez, M. and Stein P., Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract., 2007, 61, 171-80.
166. Krishna, R.; Gary, H. and Wagner J.A., Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J., 2008, 10, 401-409.
167. Deacon, C. F.; Holst, J. J. Saxagliptin: a New Dipeptidyl Peptidase- 4 Inhibitor for the Treatment of Type 2 Diabetes. Adv Ther, 2009, 26(5), 488-499.
168. Rosenstock, J.; Sankoh, S. and List, J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes. Metab., 2008, 10, 376-386.
169. Fonseca V, Zhu T, Karyekar C, Hirshberg B., Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012, 14(4), 365-71.
170. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R., Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012, 28(4), 513-23.
171. Bosi, E.; Ellis, G.C.; Wilson, C.A.; Fleck, P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obesity and Metabolism, 2011, 13 (12), 1088-1096.
172. Grogan, K., FDA wants yet more data on Takeda diabetes drug alogliptin, PharmaTimes, April 26, 2012, http://www.pharmatimes.com/Article/12-04.
173. Wang, Y.; Serradell, N.; Rosa, E.; Castaner, R. BI-1356. Drugs of the Future, 2008, 33(6), 473-477.
174. Prabavathy, N. Linagliptin- a novel dpp-4 inhibitor. Int. J. Pharma and Bio Sci., 2011, 2(1), 438-442.
175. Pattzi, H.M.; Pitale, S.; Alpizar, M.; Bennett, C.; O'Farrell A.M.; Li, J., Cherrington, J.M.; Guler, H.P. PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes. Metab., 2010, 12(4), 348-55.